• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    DCAT Week ’19

    Temperature-Controlled Logistics

    Reducing Pill Burden

    Nasal Drug Delivery

    AI in Pharma: Transforming Data into Drugs
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    AGC, Calypso Form Devt./Mfg. Deal

    Quanticate Appoints SVP of Project Delivery

    Alkermes, Clovis Form Cancer Research Collaboration

    APC Expands to U.S. with Opening of MA Facility

    Evotec & HZI Parnter for Novel Antibiotics
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    ACG Capsules Expands in Brazil

    AGC, Calypso Form Devt./Mfg. Deal

    APC Expands to U.S. with Opening of MA Facility

    Catalent Enters Clinical Supply Partnership with Adial

    Catalent Receives P&G Award
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    ACG Capsules Expands in Brazil

    Catalent Receives P&G Award

    GS1 Delivers Lightweight Messaging Standard For Verification of Product Identifiers

    Pelican BioThermal Opens New Network Location

    Reed-Lane Facility Tour
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Quanticate Appoints SVP of Project Delivery

    Alkermes, Clovis Form Cancer Research Collaboration

    APC Expands to U.S. with Opening of MA Facility

    Evotec & HZI Parnter for Novel Antibiotics

    Pii Inks Devt. Deal with Nemus
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Former FDA Senior Executives Join PAREXEL

    Top Global Pharma Company to Implement ValGenesis' VLMS

    WCG, Prudentia Enter Pharmacovigilance Alliance

    ValGenesis VLMS Chosen to Digitize Validation Process

    Serialization Compliance: Understanding the Challenges
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Jubilant HollisterStier Contract Manufacturing & Services

    Alcami

    Baxter BioPharma Solutions

    Vetter Pharma International GmbH

    Aphena Pharma Solutions, Inc.
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Ajinomoto Bio-Pharma Services

    Aphena Pharma Solutions, Inc.

    Emergent BioSolutions, Inc.

    Ascendia Pharmaceuticals

    Federal Equipment Company
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
      • Top 20 Pharma & BioPharma
      • Top 10 BioPharma Companies
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Agenda
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Breaking News

    SELLAS, Merck Enter Clinical Trial Collaboration and Supply Pact

    Combination trial with Galinpepimut-S and KEYTRUDA to be studied across in five cancers

    Related CONTENT
    • BMS, Apexigen in Opdivo Clinical Collaboration
    • Financial Report: Merck
    • Merck Teams With Aduro Biotech on Cancer Drug Trial
    • Synthetic Genomics Launches cGMP Synthetic Biology Suite
    • Celgene, Dragonfly Enter Strategic TriNKET Platform Pact
    10.03.17
    SELLAS Life Sciences Group, a development-stage biopharma company focused on cancer immunotherapies, has entered a clinical trial collaboration and supply agreement with Merck for the conduct of a combination clinical trial targeting multiple cancers. SELLAS' Wilms tumor-1 (WT1)-targeting peptide immunotherapeutic agent, galinpepimut-S, will be administered in combination with MSD's anti-PD-1 therapy KEYTRUDA in a Phase 1/2 trial enrolling patients in five cancer indications, including both hematologic malignancies and solid tumors.

    The trials aim to determine if the administration of galinpepimut-S in combination with KEYTRUDA has the potential to demonstrate clinical activity in the presence of macroscopic disease, where monotherapy with either agent would have a more limited effect. The study is based upon the presumed immunobiologic and pharmacodynamic synergy between the two agents, whereby the negative influence of tumor microenvironment factors on the immune response is mitigated by PD-1 inhibition (by KEYTRUDA) thus allowing the patients' own immune cells to invade and destroy cancerous growth deposits specifically sensitized against WT1 (by galinpepimut-S).

    The Phase 1/2 trial will study the combination in patients with WT1-positive relapsed or refractory tumors and to explore the following cancer indications: colorectal, ovarian, small cell lung, triple-negative breast, and AML. This study will assess the efficacy and safety of the combination, comparing overall response rates and immune response markers achieved with the combination versus prespecified rates based on those seen with KEYTRUDA alone.

    Galinpepimut-S is currently expected to enter a Phase III trial in patients with acute myeloid leukemia (AML) and is also in various development phases in multiple myeloma (MM) and ovarian cancer, while additional indications are expected as a monotherapy or in combination with other immuno-oncology agents.
    Related Searches
    • Phase III
    • merck
    • patients
    • immunotherapies
    Suggested For You
    Merck to Acquire Rigontec Merck to Acquire Rigontec
    Jazz, ImmunoGen in $175M Oncology Pact Jazz, ImmunoGen in $175M Oncology Pact
    AstraZeneca, Merck in $8.5B Oncology Pact AstraZeneca, Merck in $8.5B Oncology Pact
    23	Celgene 23 Celgene
    13	Lilly 13 Lilly
    11 Amgen 11 Amgen
    3 Merck 3 Merck
    2 Novartis 2 Novartis
    Invenra Enters Antibody Collaboration with Merck Invenra Enters Antibody Collaboration with Merck
    Aduro Achieves Merck Milestone Aduro Achieves Merck Milestone
    PDS, Merck Enter Keytruda Clinical Combo Alliance PDS, Merck Enter Keytruda Clinical Combo Alliance
    Celgene, Dragonfly Enter Strategic TriNKET Platform Pact Celgene, Dragonfly Enter Strategic TriNKET Platform Pact
    Synthetic Genomics Launches cGMP Synthetic Biology Suite  Synthetic Genomics Launches cGMP Synthetic Biology Suite
    Merck Teams With Aduro Biotech on Cancer Drug Trial Merck Teams With Aduro Biotech on Cancer Drug Trial
    Financial Report: Merck Financial Report: Merck

    Related Breaking News

    • Breaking News | Collaborations & Alliances | Drug Development | Industry News
      Pii Inks Devt. Deal with Nemus

      Pii Inks Devt. Deal with Nemus

      CDMO to develop dosage formulation for human dosing with NB1111 for glaucoma
      02.20.19

    • Bio News | Collaborations & Alliances | Drug Development | Industry News | Laboratory Testing | R&D
      Evotec & HZI Parnter for Novel Antibiotics

      Evotec & HZI Parnter for Novel Antibiotics

      Research activities will initially be focused on the optimization of cystobactamids
      02.20.19

    • Breaking News | Clinical Trials | Collaborations & Alliances | Drug Development | Industry News

      Gliknik Receives $15M Milestone from Pfizer

      Follows start of Phase 1 trial for Pfizer candidate PF-06755347
      02.20.19


    • Bio News | Collaborations & Alliances | Drug Development | Drug Discovery | Industry News | R&D
      PPD & HLT Enter Development Agreement

      PPD & HLT Enter Development Agreement

      To create data science-driven clinical research solutions in China with the goal of enhancing global drug development
      02.20.19

    • Breaking News | Drug Development | Industry News
      Nestlé Health Licenses Codexis’ CDX-6114

      Nestlé Health Licenses Codexis’ CDX-6114

      Novel, oral enzyme for phenylketonuria is Codexis’ first internally developed biotherapeutic candidate
      02.19.19

    • Bio News | Breaking News | Collaborations & Alliances | Drug Development | Industry News
      SK, Arvelle Sign $530M Deal for Antiepileptic Drug

      SK, Arvelle Sign $530M Deal for Antiepileptic Drug

      Mark Altmeyer named president and chief executive of Arvelle
      02.15.19


    • Bio News | Collaborations & Alliances | Drug Development | Drug Discovery | Industry News | Laboratory Testing | R&D
      Passage Bio Officially Launches

      Passage Bio Officially Launches

      With $115.5M Series A, to develop AAV-delivered therapeutics to treat rare monogenic CNS diseases
      02.15.19

    • Bio News | Collaborations & Alliances | Drug Development | Industry News | Methods Development | R&D
      Axovant Announces Formation of Arvelle Therapeutics

      Axovant Announces Formation of Arvelle Therapeutics

      Along with the strategic transition of legacy small molecule team into the newly formed company
      02.15.19

    • Bio News | Collaborations & Alliances | Drug Development | Drug Discovery | Industry News | R&D
      AbCellera & Novartis Announce Collaboration

      AbCellera & Novartis Announce Collaboration

      AbCellera to apply technology to advance programs on up to ten targets elected by Novartis
      02.15.19


    • Breaking News | Clinical Trials | Trials & Filings
      SGS to Initiate Malaria Challenge Trial in Belgium

      SGS to Initiate Malaria Challenge Trial in Belgium

      Trial to test the efficacy of MMV’s experimental compound in killing malaria parasites in the liver before they can develop and reach the bloodstream
      02.12.19

    • Breaking News | Clinical Trials | Industry News | Information Technology
      Boehringer, IBM Explore Blockchain Technology in Clinical Trials

      Boehringer, IBM Explore Blockchain Technology in Clinical Trials

      Aims to improve the quality of clinical trial processes and record keeping
      02.12.19

    • Bio News | Clinical Trials | Collaborations & Alliances | Drug Development | Drug Discovery | Industry News | R&D
      NeoTX, MedImmune Announce Clinical Collaboration

      NeoTX, MedImmune Announce Clinical Collaboration

      To support Phase 1b/2 studies investigating ANYARA in combination with AstraZeneca's IMFINZI
      02.11.19

    • Bio News | Collaborations & Alliances | Drug Development | Drug Discovery | Industry News | R&D
      Eton & Sintetica Enter Supply Agreement

      Eton & Sintetica Enter Supply Agreement

      To obtain U.S. marketing rights to two high-volume, near-term product launch candidates.
      02.11.19

    • Bio News | Breaking News | Collaborations & Alliances | Drug Development | Industry News
      3SBio, Verseau Establish Immuno-Oncology Devt. Collaboration

      3SBio, Verseau Establish Immuno-Oncology Devt. Collaboration

      3SBio will fund and conduct antibody development and GMP manufacturing
      02.11.19

    • Bio News | Collaborations & Alliances | Drug Development | Drug Discovery | Industry News | R&D
      MedPharm & Palvella Expand Partnership

      MedPharm & Palvella Expand Partnership

      For developing a new treatment for the debilitating rare disease, pachyonychia congenita
      02.11.19

    Breaking News
    • AGC, Calypso Form Devt./Mfg. Deal
    • Quanticate Appoints SVP of Project Delivery
    • Alkermes, Clovis Form Cancer Research Collaboration
    • APC Expands to U.S. with Opening of MA Facility
    • Pii Inks Devt. Deal with Nemus
    View Breaking News >
    CURRENT ISSUE

    January/February 2019

    • DCAT Week ’19
    • Temperature-Controlled Logistics
    • Reducing Pill Burden
    • Nasal Drug Delivery
    • AI in Pharma: Transforming Data into Drugs
    • Digitization: Pharma 4.0
    • Serialization Compliance: Understanding the Challenges
    • FDA & Data Integrity
    • Rising Demand for Lyophilized Products
    • Future Trends in the CDMO Space
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • privacy policy
    • term and condition
    • about us
    • contact us

    follow us

    Subscribe

    magazines

    Image
    Image
    Image
    Image
    Image
    Image
    Image
    Image
    Image
    Image
    Image

    Copyright © 2019 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login